Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients

By Buljevic Suncica   Detel Dijana   Pucar Lara   Mihelic Radovan   Madarevic Tomislav   Sestan Branko   Varljen Jadranka  

Rheumatology International, Vol. 33, Iss. 11, 2013-11 ,pp. : 2867-2874

Springer Publishing Company

Access to resources Recommend Favorite

Early decrease in serum IV-7S levels during IFN treatment predicts anti-fibrogenic effect in nonresponders with chronic hepatitis C

By Abe Shintaro   Narita Ryouichi   Hiura Masaaki   Jia Dong Mei   Tabaru Akinari   Otsuki Makoto  

Journal of Gastroenterology, Vol. 39, Iss. 3, 2004-03 ,pp. : 247-254

Springer Publishing Company

Access to resources Recommend Favorite

Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report

By  

Case Reports in Gastroenterology, Vol. 6, Iss. 2, 2012-08 ,pp. : 538-544

Karger

Access to resources Recommend Favorite

The changes of serum soluble HLA-class I and CD8 concentrations during interferon treatment of chronic hepatitis C patients

By Hagihara M.   Shimura T.   Takebe K.   Munkhbat B.   Yamamoto K.   Hosoi K.   Kagawa T.   Watanabe N.   Matsuzaki S.   Tsuji K.  

International Hepatology Communications, Vol. 6, Iss. 6, 1997-03 ,pp. : 316-323

Elsevier

Access to resources Recommend Favorite

Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus

By Sasaki Takashi  

Diabetology International, Vol. 1, Iss. 2, 2010-12 ,pp. : 90-92

Springer Publishing Company

Access to resources Recommend Favorite